An Extended Kinetics Study Of AAV Viral Vector Production

By Lucia Fernandez, Ph.D., Dan Brownell, and Junwei Sun

VintaBio employs a proprietary HEK293 clone, VintaCell™, optimized for growth in fixed-bed bioreactors, alongside a chemically defined transfection reagent, VintaFect™, to support scalable and cost-effective AAV vector production. These components are integrated into VintaProcess™, a unique manufacturing platform that uses a proprietary perfusion system with media recirculation to enhance vector yield and consistency. Traditional transient transfection methods in both suspension and adherent systems often overwhelm host cells, leading to poor recovery post-transfection, high empty capsid levels, and elevated impurities — challenges for which no robust solutions have yet been found. A distinguishing feature of VintaProcess is its physical separation of the host cells and vector-containing media, enabling extended observation of viral production through fractional harvests.

This study aims to explore the kinetics of capsid formation and impurity profiles over time, offering insights that can inform future process improvements. Access the full poster to learn more about the performance and refinement of VintaProcess.